Table 1 Patient baseline characteristics
| Â | All patients | |
|---|---|---|
(n = 50) | Missing | |
Sex | ||
 Male (%) | 34 (68.0) |  |
 Female (%) | 16 (32.0) | |
Age (y) | ||
 Median (range) | 69 (41–83) |  |
ECOG PS | ||
 0 (%) | 13 (26.0) | 2 (4.0) |
 1 (%) | 31 (62.0) | |
  ≥ 2 (%) | 4 (8.0) | |
Prior surgical resection | 25 (50.0) | Â |
Tumor location | ||
 Head (%) | 24 (48.0) |  |
 Body-Tail (%) | 26 (52.0) | |
Tumor size (cm) | ||
 Median (range) | 4.5 (2.0–18.0) | 1 (2.0) |
Extent of disease | ||
 Locally advanced (%) | 6 (12.0) |  |
 Metastatic (%) | 44 (88.0) | |
Measurable metastatic sites | ||
 Liver (%) | 26 (52.0) |  |
 Lymph node (%) | 20 (40.0) | |
 Lung (%) | 4 (8.0) | |
 Peritoneal (%) | 12 (24.0) | |
LDH, U/L | ||
 Median (range) | 205 (128–909) | 2 (4.0) |
CRP, mg/L | ||
 Median (range) | 13 (0–178) | 2 (4.0) |
CEA, ng/mL | ||
 Median (range) | 3.0 (0.7–64.1) | 1 (2.0) |
CA19–9, U/mL | ||
 Median (range) | 35.7 (1.0–43,645) | 1 (2.0) |
Histological subtype | ||
 Anaplastic type (%) | 16 (32.0) |  |
 Sarcomatoid type (%) | 4 (8.0) | |
 Undifferentiated carcinoma with OGCs (%) | 11 (22.0) | |
 NOS (%) | 19 (38.0) | |